Key result
Covid-19 mRNA boosters are linked to myocarditis, but longer dose intervals correlate with lower risk.
Why the study?
The risk of myocarditis associated with distant Covid-19 mRNA booster doses and the relation between dosing interval and myocarditis risk were less clear.
Does the dosing interval of Covid-19 mRNA vaccines affect the risk of vaccine-associated myocarditis in individuals aged 12 or older?
Case-Control (n=53,790)
Does the dosing interval of Covid-19 mRNA vaccines affect the risk of vaccine-associated myocarditis in individuals aged 12 or older?
Extending the dosing interval between Covid-19 mRNA vaccine doses, including boosters, may mitigate the risk of vaccine-associated myocarditis.
Covid-19 mRNA vaccines have been shown to be associated with a short-term increased risk of myocarditis, with the highest risk observed after the second dose compared to the first. The extent of the risk associated with more distant booster doses is less clear. Here, we aimed to assess the relation between dosing interval and the risk of myocarditis, for both the two-dose primary series and the third dose (first booster). Extending our previous matched case-control study, we included 4 890 cases of myocarditis aged 12 or more and 48 900 controls up to January 31, 2022. We found that the risk of myocarditis remained elevated after the booster dose and that longer intervals between each consecutive dose (including booster doses) may decrease the occurrence of vaccine-associated myocarditis.
No takes yet. Share an insight, caveat, or question.
Vu et al. (2022) conducted a case-control in Myocarditis (n=53,790). Covid-19 mRNA vaccination vs. Matched controls was evaluated on Risk of myocarditis. Covid-19 mRNA booster doses were associated with an elevated risk of myocarditis, but longer intervals between consecutive doses may decrease the occurrence of vaccine-associated myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: